Geron Corporation

Public.com summarizes a Strong Buy consensus from one covering analyst, with a $4 price target, highlighting Rytelo’s EU approval for LR-MDS as a key long‑term revenue driver while noting strategic efforts to educate prescribers. The analysis balances this with concerns about flat near‑term revenues, delayed IMpactMF trial catalysts into the second half of 2026, and substantial clinical, competitive, regulatory, and IP risks that could undermine the thesis.

Macroaxis reviews Geron’s trend behavior, risk profile, volatility, and analyst‑consensus context, framing GERN as a speculative biotech where portfolio construction and risk management matter more than short‑term price moves. The page presents Geron as roughly fairly valued relative to its “real value” estimate and target price, suggesting neither a clear bargain nor obvious overvaluation but emphasizing uncertainty around future cash flows and execution.

KoalaGains argues GERN is significantly undervalued, estimating a fair value range of roughly $1.50–$4.00 (midpoint around $2.75) and over 150% upside versus the then‑current price, driven by strong cash and short‑term investments of about $382 million against an enterprise value near $264 million. The report stresses that traditional earnings and cash‑flow models are not yet meaningful given negative free cash flow and lack of profitability, so the thesis hinges on successful commercialization of its late‑stage drug pipeline and acknowledges material clinical and execution risks for biotech investors.

WallStreetZen aggregates multi‑year analyst forecasts for earnings, revenue, ROA, and ROE, showing Geron’s projected revenue growth and return metrics outpacing both the U.S. biotechnology industry and the broader market, implying a strong long‑term growth profile. The page frames GERN as a high‑growth, high‑risk biotech, with wide ranges in forward earnings and revenue estimates that reflect uncertainty but still point to a favorable risk‑reward skew if pipeline execution and commercialization meet expectations.

TradingView’s consensus page reports a 1‑year price target around $3.86 for GERN, with a range from $1.00 to $6.00 based on seven analysts, and indicates that most recent ratings cluster in the Buy to Strong Buy area. The analysis emphasizes that forecasts are frequently updated and should be interpreted in the context of ongoing earnings reports and sector trends, positioning GERN as a volatile biotech with notable upside potential but typical sector risks.